Shares of Novavax (NVAX) jumped by a staggering 53.47% in 30 days from $133.54 to $204.94 at 20:40 EST on Thursday, after five consecutive sessions in a row of gains. NASDAQ Composite (NVAX) is rising 0.78% to $14,020.33, following the last session’s downward trend,
Novavax’s last close was $209.64, 36.79% under its 52-week high of $331.68.
Today’s last reported volume for Novavax is 3492631 which is 1.12% below its average volume of 3532345.
The company’s growth estimates for the present quarter is a negative 1110% and positive 15% for the next.
Year-on-year quarterly revenue growth grew by 3072.2%, now sitting on 475.6M for the twelve trailing months.
Novavax’s last week, last month’s, and last quarter’s current volatility was a positive 9.61%, a negative 0.08%, and a positive 5.15%, respectively.
Novavax’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 9.61% (last week), 5.19% (last month), and 5.15% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Novavax’s stock is considered to be oversold (<=20).
Novavax’s Stock Yearly Top and Bottom Value
Novavax’s stock is valued at $204.94 at 20:40 EST, way below its 52-week high of $331.68 and way above its 52-week low of $43.11.
Novavax’s Moving Average
Novavax’s worth is way higher than its 50-day moving average of $175.34 and way above its 200-day moving average of $176.84.
Previous days news about Novavax (NVAX)
There’s good reason to believe Novavax will rise soon. According to InvestorPlace on Tuesday, 8 June, "At the same time, Jeffries analyst Kelechi Chikere noted that Novavax reaffirmed its intention to produce 100 million monthly doses of vaccine by the end of Q3, and 150 million by the end of Q4 at the latest conference.", "This bodes well for Novavax as it moves closer to regulatory approval and should serve to push prices up."
Novavax to host Maryland governor larry hogan at site of future Novavax vaccines innovation campus and global headquarters. According to Business Insider on Wednesday, 9 June, "About Novavax Novavax, Inc.(Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. ", "These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year endedDecember 31, 2020, as filed with theSecurities and Exchange Commission(SEC). "
More news about Novavax (NVAX).